Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

Related Articles by Review for PubMed (Select 17602062)

1.

Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.

Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A.

Oncologist. 2007 Jun;12(6):727-37.

2.

Phase III clinical trials with darbepoetin: implications for clinicians.

Glaspy J.

Best Pract Res Clin Haematol. 2005;18(3):407-16. Review.

PMID:
15792914
3.

Darbepoetin alfa: a novel erythropoiesis-stimulating protein.

Cases A.

Drugs Today (Barc). 2003 Jul;39(7):477-95. Review.

PMID:
12973399
4.

Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.

Crouch Z, DeSantis ER.

Am J Health Syst Pharm. 2009 Jul 1;66(13):1180-5. doi: 10.2146/ajhp080214. Review.

PMID:
19535656
5.

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

Cersosimo RJ, Jacobson DR.

Ann Pharmacother. 2006 Jan;40(1):58-65; quiz 169-70. Epub 2005 Dec 6. Review.

PMID:
16332942
6.

Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.

Stevenson JG, Natale JJ.

Pharmacotherapy. 2007 Mar;27(3):434-46. Review.

PMID:
17316154
7.

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.

Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT.

Clin Ther. 2006 Jun;28(6):801-31. Review. Erratum in: Clin Ther. 2007 May;29(5):985-6.

PMID:
16860166
8.

Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.

[No authors listed]

Drug Ther Bull. 2004 Mar;42(3):21-3. Review.

PMID:
15038080
9.

Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa.

Valley AW.

Pharmacotherapy. 2002 Sep;22(9 Pt 2):150S-159S. Review.

PMID:
12222585
10.

Darbepoetin alfa: in patients with chemotherapy-related anaemia.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(11):1067-74; discussion 1075-7. Review.

PMID:
12749734
11.

Darbepoetin alfa: potential role in managing anemia in cancer patients.

Pirker R, Smith R.

Expert Rev Anticancer Ther. 2002 Aug;2(4):377-84. Review.

PMID:
12647980
12.
13.

Darbepoetin alfa: a novel erythropoiesis-stimulating protein.

Joy MS.

Ann Pharmacother. 2002 Jul-Aug;36(7-8):1183-92. Review.

PMID:
12086553
14.

Anemia in cancer patients: significance, epidemiology, and current therapy.

Tchekmedyian NS.

Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):17-24. Review.

15.

Practitioners' practical model for managing cancer-related anemia.

Smith RE Jr, Tchekmedyian S.

Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):55-63. Review.

16.

Darbepoetin alfa for the treatment of cancer-related anemia: an update.

Pirker R.

Expert Rev Anticancer Ther. 2004 Oct;4(5):735-44. Review.

PMID:
15485310
17.

Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.

Vansteenkiste J, Wauters I.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1347-55. Review.

PMID:
17944560
18.

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

Wauters I, Vansteenkiste J.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1383-90. doi: 10.1586/era.12.117. Epub 2012 Oct 31. Review.

PMID:
23113603
19.

Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.

Kelaidi C, Fenaux P.

Expert Opin Biol Ther. 2010 Apr;10(4):605-14. doi: 10.1517/14712591003709713. Review.

PMID:
20201708
20.

Management of anemia in patients with cancer.

Steensma DP.

Curr Oncol Rep. 2004 Jul;6(4):297-304. Review.

PMID:
15161584
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk